Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25Completed SAD/MAD dosing in KT-621 Phase 1 ...

On Tuesday morning, Galderma launched its Scratch Resistance campaign to highlight one of the most difficult symptoms of ...

A panelist discusses how real-world data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) ...

Significant research has documented the impact of atopic dermatitis on mental health. Not only does stress trigger eczema ...

Against the backdrop of Music City’s biggest weekend, leading experts and frontline clinicians will gather in downtown Nashville, Tennessee, for one of dermatology’s most impactful educational events ...

Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for ...

In a post-hoc analysis, dupilumab improved symptoms of atopic dermatitis (AD ... What were the key findings? Treatment with dupilumab and concomitant topical corticosteroids improved AD signs ...

The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain ...

AD is a growing market with an impressive pipeline of new products from current and future players in the field.

Responses to dupilumab (Dupixent) treatment were consistent across racial and ethnic groups in children with atopic ...

A new study published in the Journal of European Academy of Dermatology and Venerology showed that compared to patients on ...